Australia - Inggris - Department of Health (Therapeutic Goods Administration)

ms health pty ltd - mifepristone, quantity: 200 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; povidone - mifepristone linepharma 200 mg tablet is indicated in females of childbearing age for preparation for the action of registered prostaglandin analogues that are indicated for the termination of pregnancy for medical reasons beyond the first trimester.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

ms health pty ltd - mifepristone, quantity: 200 mg - tablet - excipient ingredients: maize starch; microcrystalline cellulose; magnesium stearate; povidone; colloidal anhydrous silica - ms-2 step is indicated in females of childbearing age for the medical termination of an intrauterine pregnancy, up to 63 days of gestation. it is recommended that the duration of pregnancy (i.e., up to 63 days gestation) be confirmed by ultrasound. in the event that an ultrasound is not possible, extra caution should be exercised. ultrasound is also useful to exclude ectopic pregnancy.

Zimbabwe - Inggris - Medicines Control Authority

china resources zizhu pharmaceutucals co ltd - mifepristone; misoprostol - tablet; oral - 200mg;200mcg

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

ms health pty ltd - misoprostol, quantity: 200 microgram - tablet - excipient ingredients: hypromellose; microcrystalline cellulose; sodium starch glycollate; hydrogenated castor oil - gymiso is indicated in females of childbearing age for the medical termination of a developing intrauterine pregnancy in sequential combination with a mifepristone 200 mg tablet, up to 49 days of gestation.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

ms health pty ltd - mifepristone -

India - Inggris - Central Drugs Standard Control Organization

cadila pharma - mifepristone, misoprostol - tablet - mifopristone 200mg, misoprostol 200 μg - 1 tablet of mifepristone 200, 4 tablets of misoprostol 200 mcg - hormones, contraceptives and related drugs - medical termination of pregnancy of up to 49 days, cervical dilatation prior to surgical termination of pregnancy in the first trimester, therapeutic termination of pregnancy for medical reasons beyond the first trimester, labor induction in case of fetal death in utero.

Amerika Serikat - Inggris - NLM (National Library of Medicine)

genbiopro, inc. - mifepristone (unii: 320t6rnw1f) (mifepristone - unii:320t6rnw1f) - mifepristone tablets, 200 mg is indicated, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation. - administration of mifepristone tablets, 200 mg and misoprostol for the termination of pregnancy (the “treatment procedure”) is contraindicated in patients with any of the following conditions: confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass (the treatment procedure will not be effective to terminate an ectopic pregnancy) [ see warnings and precautions ( 5.4)] chronic adrenal failure (risk of acute adrenal insufficiency) concurrent long-term corticosteroid therapy (risk of acute adrenal insufficiency) history of allergy to mifepristone, misoprostol, or other prostaglandins (allergic reactions including anaphylaxis, angioedema, rash, hives, and itching have been reported [ see adverse reactions ( 6.2)]) hemorrhagic disorders or concurrent anticoagulant therapy (risk of heavy bleeding) in

Amerika Serikat - Inggris - NLM (National Library of Medicine)

pci pharma services canada, inc. - mifepristone (unii: 320t6rnw1f) (mifepristone - unii:320t6rnw1f) - mifepristone tablets, 200mg is indicated, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation. - administration of mifepristone tablets, 200mg and misoprostol for the termination of pregnancy (the “treatment procedure”) is contraindicated in patients with any of the following conditions: confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass (the treatment procedure will not be effective to terminate an ectopic pregnancy) [see warnings and precautions (5.4)] chronic adrenal failure (risk of acute renal insufficiency) concurrent long-term corticosteroid therapy (risk of acute renal insufficiency) history of allergy to mifepristone, misoprostol, or other prostaglandins (allergic reactions including anaphylaxis, angioedema, rash, hives, and itching have been reported [see adverse reactions (6.2]) hemorrhagic disorders or concurrent anticoagulant therapy (risk of heavy bleeding) - confirmed or suspected ectopic pregna

Israel - Inggris - Ministry of Health

a. lapidot pharmaceuticals, ltd - mifepristone - tablets - mifepristone 200 mg - mifepristone - mifepristone - medical termination of developing intra-uterine pregnancy.- in sequential use with a prostaglandin analogue up to 63 days of amenorrhea.- softening and dilatation of the cervix uteri prior to surgical termination of pregnancy during the first trimester.- preparation for the action of prostaglandin analogues in the termination of pregnancy for medical reasons (beyond the first trimester).- labour induction in foetal death in utero.in patients where prostaglandin or oxytocin cannot be use.

Kenya - Inggris - Pharmacy and Poisons Board

mifepristone and misoprostol - tablet - mifepristone 200mg and misoprostol 1200mcg - misoprostol